[go: up one dir, main page]

UA106869C2 - Поліпептид ace2 - Google Patents

Поліпептид ace2

Info

Publication number
UA106869C2
UA106869C2 UAA200912888A UAA200912888A UA106869C2 UA 106869 C2 UA106869 C2 UA 106869C2 UA A200912888 A UAA200912888 A UA A200912888A UA A200912888 A UAA200912888 A UA A200912888A UA 106869 C2 UA106869 C2 UA 106869C2
Authority
UA
Ukraine
Prior art keywords
ace2
ace2 polypeptide
dimer
polypeptide
glycosylated
Prior art date
Application number
UAA200912888A
Other languages
English (en)
Inventor
Манфред Шустер
Ганс Лойбнер
Евелін Янзек-Гавлат
Бернгард Пеболл
Штефан Штраннер
Беттіна Ваґнер
Роберт Вейк
Original Assignee
Апейрон Біолоджікс Аґ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP08450052A external-priority patent/EP2108695A1/de
Application filed by Апейрон Біолоджікс Аґ filed Critical Апейрон Біолоджікс Аґ
Publication of UA106869C2 publication Critical patent/UA106869C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/17—Metallocarboxypeptidases (3.4.17)
    • C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Винахід належить до вироблення рекомбінантного, глікозилованого, розчинного людського димерного поліпептиду АСЕ2, де димер АСЕ2 включає дві мономерні одиниці АСЕ2, зв'язані за допомогою нековалентного зв'язку, причому поліпептидний ланцюг АСЕ2 включає послідовність SЕQ ІD NО: 1 або її ферментативно активні фрагменти. Димер використовують для вироблення фармацевтичних продуктів з подовженим періодом напівперетворення.
UAA200912888A 2007-06-12 2008-06-12 Поліпептид ace2 UA106869C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT0091307A AT505262A1 (de) 2007-06-12 2007-06-12 Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (de) 2008-04-08 2008-04-08 Ace2 Polypeptid
PCT/AT2008/000211 WO2008151347A1 (de) 2007-06-12 2008-06-12 Ace2 polypeptid

Publications (1)

Publication Number Publication Date
UA106869C2 true UA106869C2 (uk) 2014-10-27

Family

ID=39720296

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200912888A UA106869C2 (uk) 2007-06-12 2008-06-12 Поліпептид ace2

Country Status (35)

Country Link
US (3) US8586319B2 (uk)
EP (3) EP3375872A1 (uk)
JP (1) JP5731193B2 (uk)
KR (2) KR101682240B1 (uk)
CN (2) CN104450654A (uk)
AT (1) AT505262A1 (uk)
AU (1) AU2008261591B2 (uk)
BR (1) BRPI0813942B8 (uk)
CA (1) CA2692854C (uk)
CO (1) CO6270265A2 (uk)
CR (1) CR11213A (uk)
CY (2) CY1116873T1 (uk)
DK (2) DK2543724T3 (uk)
DO (1) DOP2009000282A (uk)
EA (1) EA027399B1 (uk)
EG (1) EG27095A (uk)
ES (2) ES2550390T3 (uk)
HK (1) HK1255493A1 (uk)
HR (2) HRP20151120T1 (uk)
HU (2) HUE037877T2 (uk)
IL (1) IL202653B (uk)
LT (1) LT2543724T (uk)
MA (1) MA31472B1 (uk)
MX (1) MX2009013472A (uk)
MY (1) MY180672A (uk)
NO (1) NO2543724T3 (uk)
NZ (1) NZ581704A (uk)
PL (2) PL2543724T3 (uk)
PT (2) PT2155871E (uk)
RS (2) RS57292B1 (uk)
SI (2) SI2543724T1 (uk)
TR (1) TR201808117T4 (uk)
UA (1) UA106869C2 (uk)
WO (1) WO2008151347A1 (uk)
ZA (1) ZA200908751B (uk)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en) 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US9458444B2 (en) 2006-02-03 2016-10-04 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US8946155B2 (en) 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en) 2006-02-03 2019-03-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en) 2006-02-03 2015-02-05 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2077119A1 (de) * 2007-12-21 2009-07-08 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Behandlung von Fibrosen und Lebererkrankungen
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
US12203113B2 (en) 2009-07-09 2025-01-21 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
PE20142405A1 (es) 2012-04-19 2015-01-25 Opko Biolog Ltd Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
EP2922867B1 (en) 2012-11-20 2021-07-21 OPKO Biologics Ltd. Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides
US9757433B2 (en) 2013-01-14 2017-09-12 Apeiron Biologicals AG Modified ACE2 polypeptides
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
PH12017501089B1 (en) 2014-12-10 2022-06-22 Opko Biologics Ltd Methods of producing long acting ctp-modified growth hormone polypeptides
AU2016280867B2 (en) 2015-06-19 2020-02-27 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
KR102618424B1 (ko) 2016-07-11 2023-12-26 옵코 바이오로직스 리미티드 지속성 응고 인자 vii 및 그 제조 방법
US11518788B2 (en) * 2020-07-10 2022-12-06 Avirus, Inc. Methods and compositions for treating and preventing viral infection
BR112022014552A2 (pt) * 2020-01-23 2022-10-25 Avirus Inc Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante
WO2021190980A1 (en) 2020-03-22 2021-09-30 Quadrucept Bio Limited Multimers for viral strain evolution
EP3884957A1 (en) 2020-03-26 2021-09-29 The University of British Columbia Methods for treatment of virus and methods for screening of anti-virus reagent using organoids
US20230293647A1 (en) * 2020-04-09 2023-09-21 Autolus Limited Polypeptide
WO2021217120A2 (en) * 2020-04-24 2021-10-28 Administrators Of The Tulane Educational Fund Compositions and methods for preventing or reducing the effects of infections by coronaviruses that bind the extracellular domain of the ace2 receptor
CN113667016A (zh) * 2020-05-15 2021-11-19 普米斯生物技术(珠海)有限公司 一种构建冠状病毒抗体的平台
WO2021247675A1 (en) 2020-06-02 2021-12-09 Ngm Biopharmaceuticals, Inc. Coronavirus-binding agents and uses thereof
DE102020207224A1 (de) 2020-06-09 2021-12-09 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
AU2021297998A1 (en) * 2020-06-25 2022-12-15 Gliknik Inc. ACE2-Fc fusion proteins and methods of use
WO2022008642A1 (en) 2020-07-08 2022-01-13 Apeiron Biologics Ag Treatment of sars-cov-2 infection with a combination of targets
CN116348492A (zh) * 2020-07-10 2023-06-27 生物分子控股有限责任公司 四面体抗体
WO2022037699A1 (en) * 2020-08-21 2022-02-24 Westlake University Engineered ace2 oligomers and uses thereof
KR102725210B1 (ko) * 2020-10-05 2024-11-04 한양대학교 산학협력단 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물
CN112280764A (zh) * 2020-11-18 2021-01-29 通用生物系统（安徽）有限公司 一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (en) 2020-12-11 2022-06-15 IMBA-Institut für Molekulare Biotechnologie GmbH Superior neutralization of sars-cov-2 by deglycosylated human angiotensin converting enzyme 2
US20220226489A1 (en) 2021-01-20 2022-07-21 Singh Biotechnology, Llc Therapeutics directed against coronavirus
WO2022184659A1 (en) 2021-03-01 2022-09-09 Quadrucept Bio Limited Antibody domains & multimers
WO2022207918A1 (en) 2021-04-02 2022-10-06 Apeiron Biologics Ag COVID-19 Therapy
EP4387732A4 (en) 2021-08-19 2025-09-03 Phenom Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF SARS-CoV-2
CN113897346A (zh) * 2021-09-16 2022-01-07 四川大学 能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用
KR102834587B1 (ko) * 2021-09-16 2025-07-17 인에이블앱 주식회사 안지오텐신전환효소 2 수용체 및 이의 용도
DE102023118690A1 (de) 2023-07-14 2025-01-16 Christoph Karle Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer Infektion und/oder Infektionskrankheit und/oder einer Folgeerkrankung davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989363B1 (en) * 1997-12-11 2006-01-24 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en) 1997-12-11 2003-08-26 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) * 1997-12-11 2001-02-27 Millennium Pharmaceuticals, Inc. Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
ATE415175T1 (de) 2002-06-19 2008-12-15 Univ Health Network Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
WO2004023270A2 (en) 2002-09-09 2004-03-18 Millenium Pharmaceuticals, Inc. Crystal structure of angiotensin-converting enzyme-related carboxypeptidase
EP1723962A1 (en) * 2005-05-19 2006-11-22 IMBA-Institut für Molekulare Biotechnologie GmbH Use of inhibitors of the renin-angiotensin system for the treatment of lung injuries
AT504443B1 (de) * 2006-10-19 2008-11-15 Apeiron Biolog Forschungs Und Verfahren zur bestimmung der aktivität von ace2
AT505262A1 (de) * 2007-06-12 2008-12-15 Apeiron Biolog Forschungs Und Rekombinantes ace2 polypeptid
EP2108695A1 (de) 2008-04-08 2009-10-14 Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H. Ace2 Polypeptid
AT506258A1 (de) * 2007-12-18 2009-07-15 Apeiron Biolog Forschungs Und Behandlung inflammatorischer krankheiten
AT506632A1 (de) * 2008-04-09 2009-10-15 Apeiron Biolog Forschungs Und Behandlung von tumorerkrankungen

Also Published As

Publication number Publication date
KR20100040809A (ko) 2010-04-21
HRP20151120T1 (xx) 2015-11-20
KR101682240B1 (ko) 2016-12-06
AU2008261591B2 (en) 2014-08-07
HUE028012T2 (en) 2016-11-28
DOP2009000282A (es) 2010-03-31
TR201808117T4 (tr) 2018-07-23
SI2155871T1 (sl) 2015-11-30
HUE037877T2 (hu) 2018-09-28
BRPI0813942B1 (pt) 2019-08-20
EP2155871B1 (de) 2015-08-12
IL202653B (en) 2018-01-31
EP2543724A3 (de) 2013-02-20
BRPI0813942A2 (pt) 2014-12-30
AU2008261591A1 (en) 2008-12-18
CO6270265A2 (es) 2011-04-20
US8586319B2 (en) 2013-11-19
HRP20180856T1 (hr) 2018-08-24
ES2550390T3 (es) 2015-11-06
RS57292B1 (sr) 2018-08-31
RS54340B1 (sr) 2016-02-29
EP2543724B1 (de) 2018-03-21
JP2011519264A (ja) 2011-07-07
ES2670938T3 (es) 2018-06-04
PL2155871T3 (pl) 2015-12-31
KR20160054045A (ko) 2016-05-13
ZA200908751B (en) 2010-07-28
EP2155871A1 (de) 2010-02-24
PL2543724T3 (pl) 2018-08-31
CA2692854C (en) 2017-07-04
CY1116873T1 (el) 2017-04-05
CR11213A (es) 2010-04-20
NZ581704A (en) 2012-05-25
DK2543724T3 (en) 2018-05-28
US20100310546A1 (en) 2010-12-09
PT2543724T (pt) 2018-06-11
CA2692854A1 (en) 2008-12-18
EA201000002A1 (ru) 2010-08-30
CN101796183A (zh) 2010-08-04
LT2543724T (lt) 2018-06-25
NO2543724T3 (uk) 2018-08-18
IL202653A0 (en) 2011-08-01
CN104450654A (zh) 2015-03-25
EG27095A (en) 2015-05-28
BRPI0813942B8 (pt) 2021-05-25
MA31472B1 (fr) 2010-06-01
US20180289779A1 (en) 2018-10-11
WO2008151347A1 (de) 2008-12-18
HK1136602A1 (en) 2010-07-02
CY1120426T1 (el) 2019-07-10
SI2543724T1 (en) 2018-07-31
MX2009013472A (es) 2010-06-25
EA027399B1 (ru) 2017-07-31
MY180672A (en) 2020-12-05
HK1255493A1 (zh) 2019-08-16
AT505262A1 (de) 2008-12-15
EP2543724A2 (de) 2013-01-09
DK2155871T3 (en) 2015-11-09
PT2155871E (pt) 2015-10-26
US10716833B2 (en) 2020-07-21
EP3375872A1 (de) 2018-09-19
JP5731193B2 (ja) 2015-06-10
US20140099297A1 (en) 2014-04-10

Similar Documents

Publication Publication Date Title
UA106869C2 (uk) Поліпептид ace2
EA200801460A1 (ru) Рекомбинантные моновалентные антитела и способы их получения
AR072596A1 (es) Un complejo proteico que comprende una proteina dimerica y un polimero no peptidico
AR117913A2 (es) Conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
EA201290722A1 (ru) Рекомбинантный белок эксендина-4 и его аналога, способ их приготовления и применение
WO2014052451A3 (en) Insulin analog dimers
NZ607069A (en) Modified relaxin polypeptides and their uses
WO2012175222A8 (en) AN IL-15 AND IL-15Rα SUSHI DOMAIN BASED IMMUNOCYTOKINES
BR112012017054A2 (pt) "análogo de peptídeo de oxintomodulina, seu uso, bem como composição farmacêutica"
MX2013014583A (es) Conjugados de proteina-polimero-farmaco.
PE20120429A1 (es) Proteinas de enlace de miostatina
MY176834A (en) Conjugate biologically active polypeptide monomer and immunoglobulin fc fragment with reduced receptor-mediated clearance, and the method for preparing the same
EA201491155A1 (ru) Новые мутантные про-нрф и их применение для получения бета-нрф
EA200602243A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
ES2530670T3 (es) Anticuerpo anti-FGF23 y composición farmacéutica que comprende el mismo
EA200870421A1 (ru) Димеры производных артемизинина, их получение и их применение в терапии
NZ596501A (en) Casb7439 constructs
EA201070484A1 (ru) Новые конъюгаты нейртурина для фармацевтического применения
EA200801220A1 (ru) 3-аминоциклопентанекарбоксамиды в качестве модуляторов хемокиновых рецепторов
ATE490270T1 (de) Zytokinderivate
NO20082127L (no) Antagonister mot interaksjon av PF4 og Rantes
EA201000381A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ФЕРМЕНТ ЦИПРОЗИН, АСПАРАГИНОВУЮ ПЕПТИДАЗУ ИЗ Cynara cardunculus, И ЕГО ВКЛЮЧЕНИЕ В ПРОТИВООПУХОЛЕВЫЕ КОМПОЗИЦИИ
TW200505945A (en) Oligopeptides
EA200971092A1 (ru) Vegf-d мутанты и их применение